L'athérosclérose est-elle biologiquement éliminée à des taux de LDL extrêmement bas tout au long de la vie ?

Une évaluation critique de l'hypothèse du “ risque zéro ”

athéromateux maladie cardiovasculaireLes maladies cardiovasculaires sont un terme générique qui désigne les problèmes liés au cœur et aux vaisseaux sanguins, notamment les crises cardiaques, les accidents vasculaires cérébraux et le blocage des artères des jambes. (MCV) a longtemps été présentée comme une conséquence inévitable de la sénescence humaine, bien que la biologie moléculaire contemporaine et la génétique épidémiologieL'épidémiologie est l'étude des profils de santé au sein de grands groupes de personnes : qui tombe malade, où, et ce qu'ils ont en commun. convergent de plus en plus vers un modèle dépendant du substrat dans lequel la maladie est, en principe, biologiquement évitable [1], [2]. La prémisse de l'hypothèse du “ risque zéro ” est que athéroscléroseL'athérosclérose est la maladie à l'origine de la plupart des crises cardiaques et de nombreux accidents vasculaires cérébraux. Des particules de cholestérol se coincent dans la paroi d'une artère, le corps envoie des cellules immunitaires pour nettoyer, et au fil des ans, ce désordre durcit pour former de la plaque. est principalement un apolipoprotéineUne apolipoprotéine est une protéine attachée à une particule transporteuse de graisses dans votre sang. Les graisses et l'eau ne se mélangeant pas, ces protéines agissent comme une enveloppe qui permet aux graisses de voyager en toute sécurité dans la circulation sanguine. BApoBL'ApoB est une protéine située à la surface de chaque particule de cholestérol susceptible de se coincer dans la paroi de vos artères et de provoquer de la plaque. Chacune de ces particules transporte exactement une ApoB.trouble piloté par2], [3]. En maintenant une exposition tout au long de la vie à des niveaux ultra-faibles de basse densité lipoprotéineUne lipoprotéine est un tout petit paquet qui transporte les graisses et le cholestérol dans votre circulation sanguine. Comme la graisse ne se dissout pas dans l'eau, elle a besoin d'une enveloppe protéique pour voyager. cholestérolLe cholestérol est une substance cireuse dont votre corps a besoin. Il entre dans la composition des parois cellulaires, des hormones, de la vitamine D et de la bile qui digère vos aliments. Vous en mettriez sans lui. (LDL-C) et sa concentration de particules d'ApoB correspondante — environ 10 à 20 mg/dL (0,26 à 0,52 mmol/L), proche de la valeur de base physiologique du nouveau-né — la probabilité d'initier le pathognomoniqueUn signe pathognomonique est un signe tellement spécifique d'une maladie particulière que sa seule présence suffit à confirmer le diagnostic ; dans l'hypercholestérolémie homozygote familiale (HoFH), les xanthomes cutanés et tendineux apparaissant avant l'âge de quatre ans sont considérés comme pathognomoniques car ils sont causés par un débordement de cholestérol si extrême qu'il n'est presque exclusivement observé que dans cette affection. lésionEn cardiologie, une lésion désigne une zone distincte de plaque athéromateuse rétrécissant une artère coronaire, généralement décrite par le pourcentage d'obstruction luminale qu'elle provoque. L'article décrit quatre lésions résiduelles dont le diamètre du vaisseau est trop petit pour accepter un stent après que la plus critique a été traitée. d'athérosclérose (rétention sous-endothélialeSubendothelial retention is the process by which ApoB-containing lipoprotein particles that have crossed the endothelial barrier become electrostatically bound to proteoglycans in the arterial intima and are unable to diffuse back into the bloodstream; it is considered the non-redundant first step in atherosclerosis under the response-to-retention framework. des lipoprotéines athérogènes) peut être abaissé à un niveau biologiquement négligeable [2], [4]. Ce rapport évalue si une exposition aussi ultra-faible élimine effectivement l'initiation de la maladie, ou si des voies résiduelles impliquant inflammationL'inflammation est la réponse de votre système immunitaire à une blessure ou à quelque chose qu'il traite comme un envahisseur. Elle entraîne gonflement, chaleur et cellules de nettoyage., lipoprotéine(a)La lipoprotéine(a), écrite Lp(a) et prononcée " L-P-petit-a ", est une particule de type LDL dotée d'une protéine supplémentaire très collante. [Lp(a)] et dysfonction endothélialeLa dysfonction endothéliale se produit lorsque cette fine doublure cesse de bien faire son travail. Les vaisseaux ne se dilatent pas correctement et la barrière devient plus perméable. conserver la capacité de disséminer plaque artérielleA deposit within the artery wall made up of lipids, immune cells, cellular debris, and fibrous tissue that accumulates over time and can narrow or block blood flow; also called an atherosclerotic lesion or atheroma. indépendamment de l'ApoB [5], [6].

Le modèle de réponse à la rétention : un cadre déterministe pour l'initiation

La base théorique de l'élimination biologique de l'athérosclérose repose sur hypothèse de réponse à la rétentionThe response-to-retention hypothesis is the leading mechanistic account of early atherosclerosis, holding that the initiating event is the binding and trapping of apoB-containing lipoprotein particles to proteoglycans in the arterial intima, before inflammation or foam cell formation occurs., qui identifie la rétention sous-endothéliale de lipoprotéines contenant de l'ApoB comme l'événement initiateur nécessaire et suffisant pour athérogenèseAtherogenesis is the step-by-step process of a plaque forming. [1], [7]. Alors que les modèles traditionnels mettaient l'accent sur une lésion endothéliale franche comme déclencheur principal, les données actuelles indiquent qu'un endothélium intact, bien que dysfonctionnel, endothéliumL'endothélium est la doublure ultra-mince et glissante située à l'intérieur de chaque vaisseau sanguin. Il n'a l'épaisseur d'une seule cellule. recouvre généralement les lésions précoces et intermédiaires1], [8]. L'initiation de la maladie se produit lorsque des lipoprotéines d'un diamètre inférieur à environ 70 nm — notamment LDLLe LDL, ou lipoprotéine de basse densité, est la principale particule qui transporte le cholesterol dans votre sang, et la principale qui se coince dans les parois artérielles., les résidus riches en triglycérides et la Lp(a) traversent la barrière endothéliale et pénètrent dans la tunique intimaL'intima est la couche la plus interne de la paroi d'une artère, située juste sous laL'intima est la couche la plus interne de la paroi d'une artère, située juste en dessous de la doublure lisse. [2], [7].

Molecular Interactions within the Intimal Matrix

Within the intima, retained particles interact with the matrice extracellulaireLa matrice extracellulaire est l'échafaudage de collagène et d'autres fibres qui maintient les tissus ensemble et donne à la paroi artérielle sa résistance. (ECM), particularly with negatively charged proteoglycans such as versicanVersican is a large sulfated proteoglycan found in the arterial intima whose negatively charged glycosaminoglycan chains bind ionically to apoB-100 on lipoprotein particles, contributing to their retention in the artery wall as an early step in atherosclerosis., perlecan, biglycaneBiglycan is a small leucine-rich proteoglycan present in the arterial subendothelial matrix that, along with versican and decorin, binds apoB-containing lipoprotein particles through ionic interactions, contributing to their retention in the intima as an initiating step in atherosclerosis., and decorin [1], [7]. Positively charged regions of ApoB, specifically sequences rich in lysine and arginineArginine is an amino acid found in whole foods such as walnuts that serves as the biochemical precursor the body uses to synthesize nitric oxide, thereby supporting endothelial relaxation and healthy blood vessel dilation. residues, bind electrostatically to the glycosaminoglycaneGlycosaminoglycans are long, negatively charged sugar chains that are major components of the arterial extracellular matrix and plaque connective tissue; in cynomolgus macaque plaques they are prominent structural constituents that persist after regression of the lipid-rich components. (GAG) chains of these proteoglycans [1]. This is not passive entrapment; it is a critical biochemical event that prolongs the residence time of the lipoprotein within the arterial wall by an order of magnitude relative to plasma transit [9].

Proteoglycan	Interaction with ApoB Lipoproteins	Role in Atherogenesis
Versican	Large aggregating proteoglycan that expands intimal volume	Promotes lipoprotein trapping and cellule musculaire lisseLes cellules musculaires lisses constituent la couche moyenne d'une artère et contrôlent le degré de contraction ou de relaxation du vaisseau. migration [7]
Perlecan	Basement-membrane héparane sulfateHeparan sulfate is a negatively charged glycosaminoglycan, similar to chondroitin sulfate, found on proteoglycans in the arterial extracellular matrix; alongside chondroitin sulfate, it participates in the electrostatic binding of ApoB-100–containing lipoproteins that initiates plaque formation. proteoglycan	Structural scaffold facilitating early particle retention [7]
Biglycane	Small leucine-rich proteoglycan with high ApoB affinity	Correlates with development of cœur nécrotique riche en lipidesLe cœur nécrotique riche en lipides est l'intérieur mou, gorgé de graisses et de cellules inflammatoires, d'une plaque athérosccléreuse avancée ; c'est le compartiment le plus sujet à la rupture et celui qui réagit le mieux à la baisse des lipides, ce qui peut le réduire et le stabiliser même lorsque le tissu calcifié environnant subsiste. [7]
Decorin	Interacts with collagen and LDL particles	Modulates fibrotic response and lipoprotein aggregation [7]

Prolonged intimal residence renders retained lipoproteins highly susceptible to chemical modification, including oxidation, glycation, enzymatic cleavage, and aggregation [1], [9]. Modified particles trigger a maladaptive immune response [1], [7]. Endothelial cellsThe thin layer of cells lining the inner surface of all blood vessels; they regulate vascular tone, prevent clotting, and control the passage of substances into the artery wall — and their dysfunction is an early, critical step in atherosclerosis. activated by modified lipids and mechanical stressors express adhesion molecules (VCAM-1VCAM-1 is a sticky molecule that appears on an inflamed vessel lining and grabs passing white blood cells so they can burrow into the wall., ICAM-1ICAM-1 is a molecule that appears on the surface of the blood vessel lining and acts like Velcro, catching passing immune cells.) and secrete chemokines that recruit monocytes into the espace sous-endothélialL'espace sous-endothélial est le petit espace situé juste sous la paroi interne de l'artère, entre cette simple couche de cellules et le muscle sous-jacent. [1], [10]. These monocytes differentiate into macrophagesUn macrophage est une grande cellule immunitaire qui engloutit les débris et les envahisseurs. Le nom signifie littéralement "grand mangeur"." that internalize modified lipoproteins via scavenger receptors and transform into lipid-laden cellules spumeusesUne cellule spumeuse est une cellule immunitaire qui a ingéré tellement de cholestérol piégé qu'elle gonfle et prend un aspect écumeux au microscope.—the morphological hallmark of the strie lipidiqueUne strie lipidique est le premier stade visible de l'athérosclérose : une tache jaune et plate de cellules immunitaires gorgées de cholestérol juste sous la paroi de l'artère. [10].

Thermodynamic and Kinetic Limits of Retention

The probability of particle retention is a function of the local concentration of ApoB particles and the availability of liaison aux protéoglycanesProteoglycan binding is the electrochemical interaction by which positively charged lysine- and arginine-rich regions of ApoB latch onto the negatively charged glycosaminoglycan chains of intimal matrix proteins such as biglycan, versican, perlecan, and decorin. This binding dramatically prolongs the residence time of a lipoprotein particle within the artery wall, making it far more susceptible t… sites within the matrix [7]. In a stochastic model of the arterial wall, the rate of lipid accumulation is determined by the flux of lipoproteins into the intima and the kinetics of proteoglycan binding [9]. At ultra-low circulating concentrations (e.g., LDL-C ≈ 15 mg/dL), the number of particles available for transcytoseTranscytosis is the process by which a cell picks something up on one side, carries it across, and releases it on the other. is vastly reduced [2], [11].

If the rate of particle entry is low enough that the arterial wall’s endogenous clearance mechanisms—macrophage-mediated phagocytosis and HDL-mediated transport inverse du cholestérolReverse cholesterol transport is the process of moving cholesterol out of tissues, including artery walls, and back to the liver for disposal. HDL particles do the hauling.—can remove particles before pro-inflammatory modification, the inflammatory cascade is never initiated [1], [12]. This is the mechanistic basis for a biological “no-effect” threshold for ApoB concentration, below which the probability of initiating a lesion approaches zero [7].

The Quantitative Relationship of Cumulative Exposure: Plaque-Years

Clinical risk of ASCVD reflects not instantaneous LDL-C but the integral of exposure over time, a concept now formalized as “cumulative LDL exposure” or “années-plaquesPlaque-years is a measure of cumulative lifetime exposure to LDL cholesterol, calculated as the integral of LDL-C concentration over time (approximated as LDL-C × age), used to quantify the total atherogenic burden an artery wall has experienced. Research has identified heuristic thresholds—around 5,000 for low risk and above 14,000 for very high risk—that correspond to progressively greater prob…” [13], [14]. Under this framework, atherosclerosis is a disease of gradual substrate accumulation, and the time to a clinical event is determined by how quickly an individual crosses a personal plaque thresholdThe plaque threshold is the individual-specific cumulative level of atherogenic lipoprotein exposure at which enough lesion burden has accumulated to produce a clinically meaningful cardiovascular event such as a heart attack or stroke. Risk factors such as hypertension, diabetes, and smoking effectively lower this threshold, meaning events occur at a smaller cumulative exposure, while a metaboli… [13]. Domanski and colleagues formally demonstrated in a pooled analysis of 4,958 participants from ARICARIC, the Atherosclerosis Risk in Communities study, has followed thousands of American adults since the late 1980s., CARDIACARDIA has followed young adults from their twenties into later life, tracking fitness, cholesterol, blood pressure, and what eventually happened to them., MESAMESA, the Multi-Ethnic Study of Atherosclerosis, followed thousands of adults with no known heart disease, scanning their arteries and tracking outcomes., and the Framingham Offspring Study that the cumulative burden of LDL-C exposure, the time course of that exposure, and the slope of LDL-C change over time each independently predicted incident cardiovascular events [14].

Defining the Plaque-Year Thresholds

Analysis of epidemiologic and Randomisation mendélienneMendelian randomization is a clever research method that uses the genes people were born with as a natural experiment. data permits tentative quantification of cumulative-exposure thresholds [13], [15]. Published thresholds remain approximate and cohort-dependent rather than formally validated across populations, and the values below are best regarded as heuristic estimates drawn from long-term cohort and Mendelian randomisationLa randomisation est le processus qui consiste à assigner les participants à un essai à des groupes de traitement ou témoins par le hasard, garantissant ainsi que les facteurs de confusion connus et inconnus sont répartis de manière égale ; lorsque la randomisation échoue — comme l'ont constaté des auditeurs dans le cas de PREDIMED —, les groupes peuvent différer d'une manière qui fausse l'effet apparent du traitement. data [13]–[15].

Risk Metric (Men)	Approx. Cumulative LDL Exposure (g·yr/dL)	Lifetime Major Event Risk (approx.)
Low-Risk Threshold	~ 5,000	< 10% probability of event [13], [14]
Intermediate Threshold	~ 8,000	Approximate median age for non-zero CAC (~age 55–60) [13], [16]
High-Risk Threshold	~ 11,000	>20% probability of event [13], [14]
Very High-Risk Threshold	~ 14,000	Approximate median age for CAC ≥ 100 [13], [16]

Note: Thresholds for women are generally higher (estimated by roughly 20–30% at comparable risk strata), consistent with the observed later-life onset of ASCVD in women and premenopausal attenuation of LDL transcytosis and arterial-wall biology [13].

Influence of Secondary Risk Factors on the Retention Threshold

Cumulative LDL exposure required to initiate events is not static; it is modulated by the biological environment of the artèreUne artère est un vaisseau sanguin qui transporte le sang du cœur vers le reste du corps. [13]. HypertensionL'hypertension est le terme médical pour la pression artérielle élevée., diabèteLe diabète est une affection où la glycémie reste trop élevée, soit parce que l'organisme produit trop peu d'insuline, soit parce qu'il cesse de répondre à l'insuline qu'il produit., et tabagismeLe tabagisme endommage la paroi de vos vaisseaux sanguins, élève la tension artérielle, favorise la coagulation du sang et accélère la formation de plaques d'athérome. effectively lower the threshold by increasing particle retention or accelerating inflammatory response to retained lipids [2], [17].

• Hypertension: Elevated tension artérielleLa pression artérielle est la force du sang qui pousse contre la paroi de vos artères. Elle s'écrit sous la forme de deux chiffres, comme 120/80. Le chiffre du haut correspond à la pression lorsque votre cœur se contracte, et celui du bas lorsqu'il se relaxe. increases LDL transcytosis across the endothelium and promotes synthesis of proteoglycans with higher ApoB affinity [7]. Shear stress on existing plaquesLa plaque est une accumulation de cholestérol, de cellules immunitaires, de tissu cicatriciel et de calcium à l'intérieur de la paroi d'une artère. raises rupture likelihood [13].
• Type 2 diabetes / résistance à l'insulineLa résistance à l'insuline se produit lorsque vos cellules cessent de bien réagir à l'insuline, ce qui oblige votre pancréas à en produire de plus en plus pour faire le même travail.: Chronic dysglycemia and hyperinsulinemia injure the arterial wall, promote adverse remodeling, and narrow the coronary lumensLe lumen est le canal ouvert à l'intérieur d'un vaisseau sanguin par lequel le sang circule réellement., so even small plaques become hemodynamically significant and thrombi more likely to be occlusive [14].
• Smoking: Tobacco exposure causes direct endothelial damage and stress oxydatifLe stress oxydatif est un déséquilibre entre des molécules réactives dommageables et la capacité de l'organisme à les neutraliser., accelerating intimal lipoprotein modification [2].
• Androgen abuse: In young male anabolic-androgenic steroid users, volume de la plaque dentaireLe volume de plaque est la quantité physique totale de plaque dans un segment d'artère, mesurée en millimètres cubes. et score calcique coronaireLe calcium coronaire est une mesure des dépôts de plaque calcifiée dans les parois des artères coronaires, quantifiée par scanner et exprimée par un score d'Agatston ; des scores plus élevés indiquent une charge de plaque cumulative plus importante et prédisent de futurs événements cardiovasculaires. scores correlate strongly with lifetime exposure, consistent with an independent acceleration of atherogenesis [18].

For a metabolically healthy individual with controlled blood pressure and no inflammatory comorbidity, the arterial wall can tolerate a higher cumulative burden before clinical disease manifests [13]. Under the zero-risk hypothesisThe zero-risk hypothesis proposes that atherosclerosis is not an inevitable consequence of aging but a substrate-dependent disease that requires sustained exposure to ApoB-containing lipoproteins to initiate; if lifelong circulating ApoB and LDL-C are kept near newborn baseline levels (roughly 10–20 mg/dL), the probability of initiating any atherosclerotic lesion approaches zero., maintaining LDL-C ≈ 15 mg/dL across an 80-year lifespan yields only ~1,200 g·yr/dL of exposition cumulativeL'exposition cumulative est la quantité totale de particules de cholestérol nocives auxquelles vos artères ont été exposées tout au long de votre vie — c'est-à-dire l'intensité multipliée par la durée.—well below the ~5,000 g·yr/dL heuristic low-risk threshold and roughly an order of magnitude below thresholds associated with clinically meaningful event probabilities [13].

Genetic Null Models: Experiments of Nature

The most rigorous test of whether atherosclerosis can be eliminated lies in human genetic models of lifelong ultra-low ApoB exposure [2], [3]. These “experiments of nature” provide the strongest available evidence that, in the near-absence of particules athérogènesLes particules athérogènes sont les lipoprotéines contenant de l'ApoB — notamment les LDL, IDL, VLDL et la lipoprotéine(a) — qui peuvent pénétrer et être retenues dans la paroi artérielle pour initier et alimenter la croissance de la plaque ; l'article utilise ce terme pour décrire ce qui doit être abaissé de manière substantielle et durable pour obtenir la régression de la plaque., disease initiation is profoundly attenuated [19], [20]. Case-report numbers remain small and autopsy data are limited, so claims of “complete” absence should be interpreted as “markedly reduced burden beyond what is plausibly attributable to chance alone” rather than mathematically zero.

Abetalipoproteinemia (ABL) and MTTP Deficiency

Abetalipoproteinemia is an autosomal recessive disorder caused by biallelic loss-of-function mutations in MTTP, which is essential for assembly and secretion of ApoB-containing lipoproteins in the liver and intestine [19], [21]. Affected individuals have near-total absence of ApoB-containing lipoproteins in circulation; cholestérol totalLe cholestérol total additionne le cholestérol de toutes vos particules, qu'elles soient nocives ou bénéfiques. is typically < 30 mg/dL and LDL-C < 5 mg/dL (often undetectable) [19].

Despite severe non-cardiac pathology (fat malabsorption, acanthocytosis, spinocerebellar degeneration, retinitis pigmentosa), clinical and limited autopsy evidence indicate a striking paucity of atherosclerotic lesions in ABL patients [19], [21]. CardiomyopathyCardiomyopathy is disease of the heart muscle itself, rather than of the arteries feeding it. and arrhythmias, when they occur, are attributed predominantly to fat-soluble vitamin deficiency (vitamin E) rather than ischémieL'ischémie se produit lorsqu'un tissu ne reçoit pas assez de sang et d'oxygène pour ce qu'il est appelé à faire. [19]. ABL thus functions as the closest available human null model for ApoB-driven atherosclerosis.

Familial Hypobetalipoproteinemia (FHBL)

FHBL results from heterozygous or biallelic APOB mutations producing truncated, secretion-incompetent protéinesLes protéines sont le nutriment que votre corps utilise pour développer et réparer les muscles et les tissus. [22].

• Heterozygous FHBL: LDL-C typically 20–50 mg/dL, with markedly reduced lifetime ASCVD risk [22], [23].
• Homozygous / compound heterozygousCompound heterozygous describes a genetic state in which an individual inherits two different pathogenic mutations in the same gene—one from each parent—rather than two copies of the identical mutation; in HoFH, compound heterozygosity for two distinct LDLR mutations still abolishes or severely impairs LDL receptor function and produces the full HoFH phenotype. FHBL: LDL-C often < 10 mg/dL; phenotype resembles ABL and exhibits similarly marked protection against atherosclerotic disease on imaging and in available autopsy reports [22], [23].

Genetic Disorder	Mécanisme	LDL-C (mg/dL)	ASCVD Phenotype
Abetalipoproteinemia	MTTP LOF; no particle assembly	< 5	Markedly reduced / absent plaque [19]
Homozygous FHBL	APOB LOF; truncated proteins	< 10	Markedly reduced / absent plaque [22], [23]
PCSK9Le PCSK9 est une protéine produite par votre foie qui détruit les points d'amarrage que votre foie utilise pour éliminer le cholestérol de votre sang. LOF (compound het.)	Enhanced LDLRLDLR est le gène qui code pour le récepteur des LDL, le point d'amarrage que votre foie utilise pour extraire les particules de cholestérol de la circulation. recycling; rapid LDL clearance	~ 14–15	Healthy phenotype; no documented ASCVD in index case [24]
ANGPTL3L'ANGPTL3 est une protéine qui ralentit la dégradation des particules riches en triglycérides dans le sang. Deficiency	Increased LPL/EL activity; low TG and LDL	~ 30–40	Markedly reduced CAD (~34–41% lower odds) [25], [26]

PCSK9 and ANGPTL3: The “Healthy” Ultra-Low Phenotype

Unlike ABL, which carries severe non-cardiac morbidity, loss-of-function variants in PCSK9 and ANGPTL3 produce ultra-low LDL-C without fat malabsorption or hepatic steatosis [3], [27]. The first reported compound heterozygous PCSK9 LOF individual, a healthy fertile African American woman described by Zhao and colleagues, had an LDL-C of approximately 14 mg/dL (0.36 mmol/L) and was clinically unremarkable, demonstrating that lifelong near-absence of circulating PCSK9 is compatible with normal human physiology [24]. In the Atherosclerosis Risk in Communities (ARIC) cohort, heterozygous PCSK9 LOF variants (PCSK9 Y142X and C679X) were associated with a 28% lower LDL-C and an 88% reduction in maladie coronarienneLa coronaropathie est le rétrécissement ou le blocage des artères qui irriguent le muscle cardiaque, causé par l'accumulation de plaque athéromateuse ; c'est la principale cause de crise cardiaque et de mort cardiaque dans le monde. incidence over approximately 15 years in Black participants, with a more modest ~47% reduction tied to PCSK9 R46L carriers in White participants [28]. Extended over a lifetime of exposure, the risk reduction approaches the near-complete protection observed in ABL and homozygous FHBL [2].

ANGPTL3 deficiency produces “combined hypolipidemia” with low LDL-C, HDL-C, and triglycéridesLes triglycérides constituent la principale forme de graisse dans votre sang et dans les réserves de votre corps. [27]. In Stitziel’s 2017 analysis, three compound-heterozygous individuals had zero coronary plaque on CT angiography versus a mean 39% charge athéromateuseLa charge de plaque est la quantité totale de plaque dans vos artères, partout — et non seulement au pire endroit. in matched relatives; heterozygous LOF carriers exhibited approximately 34% lower odds of maladie coronarienneLa maladie coronarienne est une accumulation de plaque dans les artères qui irriguent le muscle cardiaque. (OR 0.66; 95% CI 0.44–0.98) [25]. Dewey and colleagues replicated this signal in 58,335 DiscovEHR participants, reporting a 41% lower odds of CAD (OR 0.59; 95% CI 0.41–0.85; p = 0.004) [26]. Critically, quantitative imaging confirms that ANGPTL3 LOF carriers do not have increased hepatic fat, distinguishing this pathway as a favorable target for long-term pharmacological mimicry [27].

Pharmacologic Evidence: The “Lower Is Better” Paradigm

Genetic models speak to lifelong exposure; pharmacologic trials test the effect of lowering LDL-C later in life, typically in individuals with existing subclinical or clinical disease [2].

Meta-Regression and the Linearity of Benefit

Data from the Cholesterol Treatment Trialists (CTT) Collaboration and subsequent non-statin trials (ézétimibeL'ézétimibe est un comprimé qui empêche vos intestins d'absorber le cholestérol., Inhibiteurs de PCSK9Un inhibiteur de la PCSK9 est un médicament qui bloque cette protéine destructrice de cholestérol, laissant plus de sites de liaison disponibles pour éliminer les particules du sang.) demonstrate a remarkably consistent relation dose-effetUne relation dose-effet signifie qu'une plus grande quantité de quelque chose produit un effet plus important, selon un gradient constant.: every 1 mmol/L (38.7 mg/dL) reduction in LDL-C corresponds to approximately a 22% reduction in major vascular events per year of treatment, with the relationship remaining linear even at the lowest achieved levels examined [29], [30]. This relationship is effectively agnostic to the mechanism by which LDL-C is lowered [15], [31].

Essai cliniqueUn essai clinique est une étude dans laquelle des chercheurs administrent un traitement à un groupe et un placebo ou des soins standard à un autre groupe, puis comparent les résultats. / Analysis	Achieved LDL-C (mg/dL)	Principal constat
CTT Meta-analysisUne méta-analyse combine statistiquement les résultats de nombreuses études distinctes en une seule estimation globale.	Range 60–180	~22% RR reduction per 1 mmol/L (38.7 mg/dL) [29]
IMPROVE-ITL'étude IMPROVE-IT a ajouté de l'ézétimibe à une statine après une crise cardiaque, testant si la réduction du LDL par un mécanisme autre qu'une statine serait bénéfique. (ezetimibe + simvastatin)	53.7 vs 69.5 (TWA)	HR 0.936 (0.89–0.99) for primary endpoint; benefit beyond statineUne statine ralentit l'enzyme que votre foie utilise pour fabriquer le cholesterol. Votre foie réagit en extrayant plus de cholesterol de votre sang, ce qui est la veritable source de bienfaits. alone [30]
FOURIERFOURIER a évalué l'évocumab, un inhibiteur de PCSK9, chez des patients présentant déjà une maladie cardiovasculaire et traités par des statines. (évocumabL'évoculumab est un médicament injectable contre le cholestérol de la famille des inhibiteurs de la PCSK9, administré généralement toutes les deux à quatre semaines.)	Median ~30 (subgroup <20)	Linear benefit continued to LDL-C < 20 mg/dL [32], [33]
ODYSSEYODYSSEY OUTCOMES a évalué l'alirocumab chez des patients se remettant d'une crise cardiaque récente. OUTCOMES (alirocumabL'alirocumab, vendu sous le nom de Praluent, est un anticorps injectable qui bloque PCSK9, administré toutes les deux à quatre semaines.)	~53 (48-wk mean)	HR 0.85 MACE; first mortality signal for PCSK9i (HR 0.85) [34]
PROLONG-ANG3 (solbinsiran)	Phase 2; sustained reduction	siRNA targeting ANGPTL3; durable ApoB and TG lowering [35]
CORALreef Lipids (enlicitide)	~60 on background statin	Oral PCSK9 inhibitor; Phase 3 LDL-C reduction [36]

The significance of these pharmacologic data lies in the “no-plateau” observation [32], [37]. Event reduction continues linearly even at achieved LDL-C below 20 mg/dL, suggesting that the biological drivers of atherosclerosis remain substrate-limited at the extremes of the lipid spectrum [2], [32].

Residual Disease versus New Initiation

A critical distinction must be drawn between primary and prévention secondaireLa prévention secondaire consiste à traiter une personne ayant déjà eu une crise cardiaque, un accident vasculaire cérébral ou la pose d'un stent, afin d'en empêcher une récidive. [13]. Among trial participants achieving very low LDL-C, a meaningful fraction still experience events [38]. This risque résiduelLe risque résiduel est le risque qui subsiste après avoir fait ce qui est évident — cholestérol traité, tension artérielle contrôlée, non-tabagisme. is not a failure of the zero-risk hypothesis but rather the predictable consequence of the irreversible structural features of advanced plaque [2]. Once a lesion has developed a cœur nécrotiqueLe cœur nécrotique est le centre mort et ramolli d'une plaque avancée, constitué de cellules immunitaires qui ont consommé le cholestérol piégé avant de mourir sur place. and a thinned chape fibreuxLa chape fibreuse est la couche de tissu résistante qui recouvre une plaque, séparant son noyau graisseux de la circulation sanguine., rupture can be triggered by local mechanical forces or systemic inflammation largely independent of current LDL-C [2], [39]. The zero-risk hypothesis concerns disease initiation, not terminal rupture of pre-existing plaque [1]. Were ultra-low lipoprotein levels maintained from birth, the substrate for acute events (mature, unstable plaqueAn unstable plaque is an atherosclerotic lesion with a thin fibrous cap, a large lipid-rich necrotic core, and active inflammation, making it prone to rupture even when it is not large enough to meaningfully restrict blood flow or cause symptoms.) would simply fail to form [2], [14].

Residual Risk Pathways: Can Inflammation or Lp(a) Initiate Disease Alone?

Falsifying the zero-risk hypothesis requires identifying a non-ApoB pathway capable of independently initiating atherosclerosis in the absence of atherogenic lipoproteins [5], [6].

Lipoprotein(a) and the Structural Necessity of ApoB

Lp(a) is a complex particle consisting of an LDL-like ApoB-100ApoB-100 is the full-length form of apolipoprotein B found on LDL, VLDL, IDL, and remnant lipoproteins; its positively charged amino-acid domains bind ionically to negatively charged proteoglycan side chains in the arterial wall, physically trapping the particle in the intima and initiating plaque formation. core covalently bound to apolipoprotein(a) [40]. It is independently associated with ASCVD risk even when LDL-C is optimally controlled [5]. Mechanistically, Lp(a) is more atherogenic than LDL on a per-particle basis because of its propensity for matrix binding and its cargo of oxidized phospholipids (OxPLs), which drive robust inflammation [40], [41]. Critically, however, every Lp(a) particle requires an ApoB-100 scaffold; in ABL and homozygous FHBL, Lp(a) cannot be synthesized because ApoB secretion is absent [19], [22]. Thus, Lp(a) does not represent a non-ApoB initiation pathway but a quantitatively more atherogenic subclass of the ApoB-containing lipoprotein family.

Inflammation as a Potentiator, Not an Initiator

The role of inflammation (IL-6L'interleukine-6, ou IL-6, est une molécule de signalisation que le système immunitaire utilise pour diffuser un message inflammatoire dans tout le corps., IL-1β, hsCRP) in ASCVD is well established, and the CANTOS trialThe CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) trial was a landmark randomized controlled trial that tested whether canakinumab, an IL-1β inhibitor, could reduce cardiovascular events in high-risk patients with elevated hs-CRP after myocardial infarction; its positive results provided the first direct clinical evidence that inflammation is a causal, therapeutically modifiabl… demonstrated that canakinumab-mediated blockade of IL-1β reduces cardiovascular events without changing lipid levels [42]. Nevertheless, current consensus is that inflammation operates as a physiologic response of the arterial wall to retained lipoproteins rather than as an autonomous initiator [7]. In wild-type animal models, systemic inflammation does not generate atherosclerosis in the absence of hyperlipidemia [43]. Arterial-wall inflammation, monocyte recruitment, and foam-cell formation are downstream consequences of lipoprotein retention [1]. Chronic inflammatory diseases (e.g., polyarthrite rhumatoïdeRheumatoid arthritis is an autoimmune disease in which the immune system attacks the joints., SLE) lower the threshold for retention-driven lesion formation, but they do not initiate atherosclerosis where the ApoB substrate is absent [7].

Imaging the Ultra-Low End: Subclinical Evidence

Score calcique coronaireA non-contrast, ECG-gated CT scan that detects and quantifies calcified plaque in the coronary arteries; the resulting Agatston score reflects the extent of coronary calcification and serves as a direct, disease-based measure of atherosclerotic burden rather than a statistical estimate of risk., échographie intravasculaireL'échographie intravasculaire, ou IVUS, utilise une minuscule sonde ultrasonore introduite à l'intérieur d'une artère coronaire pour photographier la paroi de l'intérieur. (IVUS), tomographie par cohérence optiqueLa tomographie par cohérence optique, ou OCT, introduit une sonde à base de lumière dans une artère coronaire. Elle offre des détails environ dix fois plus fins que l'échographie. (OCT), and angioscanner coronaireL'angio-coronaroscopie par TDM, ou coroscanner, est un examen tomodensitométrique réalisé avec un produit de contraste injecté dans vos veines qui produit des images détaillées des artères de votre cœur. (CCTA) provide complementary windows into the presence and composition of subclinical plaque at extreme lipid strata [16], [44].

The Power of Zero CAC

A CAC score of zero is a robust marker of low short-term event risk, but its interpretation is age-dependent [16], [45]. In younger populations (age < 45), zero CAC is common even among those with significant LDL exposure because calcificationLa calcification se produit lorsque du calcium se dépose dans une plaque, durcissant une partie de celle-ci pour la rendre semblable à de l'os. is a late-stage stabilization marker [45]. Conversely, zero CAC in an elderly individual is uncommon and identifies exceptional resistance to atherogenesis, often associated with genetically low ApoB or favorable matrix biology [16], [46].

CAC Category	Agatston UnitsAgatston units are the standardized scoring units used to quantify coronary artery calcium on a CT scan, calculated from the density and area of calcified lesions; a score of zero indicates no detectable calcified plaque, while scores of 300 or above — found exclusively in the athlete group in the UK Masters study — reflect heavy calcification.	Clinical Significance
Zero	0	No detectable calcification; very low short-term ASCVD risk [16]
Mild	1–99	Early atherosclerotic burden; supports risk up-classification [16]
Modéré	100–399	Significant plaque; 10-yr event risk typically exceeds 7.5% [16]
Grave	≥ 400	Very high risk; often treated as ASCVD equivalent [16]

IVUS and the Threshold for Regression

Intravascular imaging trials consistently show that deep LDL-C lowering can reverse net plaque burden [47], [48]. Le essai ASTEROIDUne étude historique par IVUS en série menée en 2006, dans laquelle la rosuvastatine à la dose de 40 mg par jour pendant 24 mois a produit des réductions statistiquement significatives à la fois du volume pourcent d'athérome et du volume total d'athérome, fournissant ainsi la première preuve à grande échelle qu'un traitement intensif par statines peut faire régresser la plaque coronaire. achieved mean LDL-C of 60.8 mg/dL with rosuvastatineLa rosuvastatine, vendue sous le nom de Crestor, est la statine la plus puissante disponible et reste en grande partie dans le foie plutôt que de se propager dans le corps. 40 mg and demonstrated regression of volume d'athérome en pourcentageLe volume en pourcentage d'athérome, ou PAV, est la proportion d'un segment artériel occupée par la plaque plutôt que par la lumière libre. (PAV) across multiple imaging parameters [47]. SATURNESATURN a comparé directement les deux statines les plus puissantes à dose maximale, en mesurant la plaque coronaire par échographie intravasculaire. corroborated regression at LDL-C in the 60–70 mg/dL range [48]. GLAGOVGLAGOV a ajouté un inhibiteur de PCSK9 à un traitement par statine et a mesuré la plaque coronaire par échographie intravasculaire avant et après. extended the relationship into the PCSK9-inhibitor era, showing continuous linear regression with evolocumab down to LDL-C < 40 mg/dL, with no apparent plateau [49].

• Regression: Reduction in PAV is observed consistently when LDL-C falls below ~70 mg/dL, with the magnitude of regression scaling with the depth of LDL-C reduction [47]–[49].
• Stabilization: At ultra-low levels, plaques undergo beneficial remodeling; the lipid-rich core shrinks and the fibrous cap thickens and becomes collagen-rich, converting a “vulnerable” lesion into a structurally stable one [49], [50].

Under the zero-risk hypothesis, early-life maintenance of LDL-C ≈ 15 mg/dL would prevent formation of the lipid-rich core entirely; regression and stabilization become moot because there is no lesion to regress [2].

Temporal Considerations: Early-Life Exposure versus Adult Intervention

The cumulative-exposure framework emphasizes that the age at which LDL lowering begins matters as much as its intensity [13].

The Window of Opportunity

Ference and colleagues’ landmark 2012 Mendelian randomization analysis pooled nine SNPs across six LDL-regulating genes and found that each standard unit of genetically lower LDL-C produced approximately a three-fold greater proportional reduction in coronary heart disease than the same magnitude of late-life statin-induced LDL-C lowering [15]. Specifically, lifelong exposure to ~1 mmol/L lower LDL-C was associated with roughly a 54–55% reduction in CHD risk, versus approximately a 22% risque relatifLe risque relatif compare deux groupes : ce groupe a enregistré 30 pour cent d'infarctus en moins que cet autre groupe. reduction per mmol/L with statin therapy initiated in midlife [15], [29]. This discrepancy arises because early intervention prevents lesion initiation, whereas late intervention merely slows progression of already-mature plaques [2], [14].

For a metabolically healthy individual:

• Maintaining LDL-C ≈ 15 mg/dL lifelong: Prevents plaque initiation; lifetime risk approaches zero [2], [15].
• Reducing LDL-C to ≈ 15 mg/dL at age 40: Halts further progression, stabilizes existing subclinical plaque, and delays clinical events by an estimated 10–20 years depending on baseline plaque burden [13], [14].
• Reducing LDL-C to ≈ 15 mg/dL after a clinical event: Reduces recurrence risk by stabilizing plaques vulnérablesUne plaque vulnérable est une plaque qui présente un risque élevé de se fissurer : une coque mince, un grand cœur graisseux, une inflammation active et souvent un renflement vers l'extérieur de l'artère.; does not eliminate residual risk arising from irreversible structural damage [34], [50].

The biological primacy of primary—and ideally primordial—prevention follows directly: maintaining physiologic lipoprotein levels from the earliest stages of life avoids the transition from subclinical to clinically dangerous burden [3].

Theoretical and Mechanistic Limits: Stochastic versus Zero Risk

Is the elimination of atherosclerosis absolute, or does a biological floor persist?

Stochastic Retention at Extreme Lows

Atherosclerosis initiation is fundamentally a probabilistic process [7]. Even at LDL-C ≈ 15 mg/dL, an ApoB particle could in principle enter the arterial wall, bind a proteoglycan, and undergo oxidation [7]. However, the probability of enough such particles being retained in a single focal region to trigger a self-perpetuating inflammatory response becomes vanishingly small at ultra-low concentrations [7], [9].

Arterial-wall biology incorporates multiple fail-safe mechanisms:

• Resident scavenging: Healthy intimal macrophages can clear small quantities of modified lipoprotein without becoming foam cells or secreting pro-inflammatory cytokines [1].
• HDLLe HDL, ou lipoprotéine de haute densité, est la particule souvent appelée " bon cholestérol ". Il récupère le cholestérol des tissus et le ramène vers le foie./ApoA-I efflux: HDL functions as a bidirectional lipid vector capable of removing excess cholesterol from the intima; at low ApoB influx, efflux capacity easily maintains homeostatic balance [8], [51].
• Matrix integrity: In the absence of sustained lipid retention, the intima remains thin and structurally intact, with preserved elastic fibresLes fibres sont la partie des aliments d'origine végétale que votre corps ne peut pas digérer. On les trouve dans les haricots, l'avoine, les légumes, les fruits et les grains entiers. and minimal proteoglycan expansion [9].

At the zero-risk target of LDL-C ≈ 15 mg/dL, the probability of plaque initiation may not be mathematically zero but is effectively zero in biological and clinical terms: accumulation would never reach the critical mass required for disease within a human lifespan [2], [14]. Le Étude HorusThe Horus study used CT imaging to assess 137 mummies from four ancient populations spanning more than 4,000 years, finding probable or definite atherosclerosis in 34 percent, demonstrating that arterial disease predates modern industrialized diet and lifestyle. of 137 mummies across 4,000 years of history—including Tsimane-like pre-industrial and ancient peoples—documents vascular calcification in every era examined, but notably, pre-industrial populations with very low LDL-C (e.g., the contemporary TsimaneLes Tsimane sont une population indigène de chasseurs-cueilleurs et horticulteurs de l'Amazonie bolivienne dont le mode de vie traditionnel — caractérisé par une activité physique élevée et un faible taux de cholestérol LDL moyen d'environ 91 mg/dL — est associé à des taux remarquablement bas de calcification coronarienne, 85 pour cent des adultes de plus de 40 ans ne présentant aucun calcium coronarien détectable., with mean LDL-C ~91 mg/dL and the lowest prevalence of coronary atherosclerosis measured in any human population) exhibit only low rates of subclinical CAC even in the elderly [52], [53]. Extrapolating to lifelong LDL-C of 15 mg/dL implies burden far below even this baseline.

Synthesis of the Zero-Risk Hypothesis Outcomes

Three hypothesis variants can be tested against the evidence reviewed above.

Strong Form: Zero-Risk Hypothesis

Lifelong LDL-C ≈ 15 mg/dL in a metabolically healthy individual produces effectively zero probability of clinically meaningful atherosclerosis. Evaluation: supported by human genetic null models (ABL, homozygous FHBL) where atherosclerotic burden is markedly reduced or absent [19], [22], by the physiologic newborn LDL-C baseline, and by the consistent absence of events in ultra-low-exposure genetic cohorts [2], [24].

Weak Form: Asymptotic Hypothesis

Risk approaches zero but never fully reaches it because of stochastic retention or non-ApoB pathways. Evaluation: supported by the fundamentally probabilistic nature of particle–wall interactions [7]. Extreme age or severe systemic inflammation could, in principle, cause minimal intimal changes, though such lesions would likely remain subclinical across the human lifespan [7].

Null Hypothesis

Atherosclerosis still occurs at meaningful rates independent of LDL at very low levels. Evaluation: refuted for the ideal phenotype [2], [15]. Residual risk observed in treated secondary-prevention populations is consistently attributable to pre-existing plaque and to non-LDL particules contenant de l'ApoBLes lipoprotéines — y compris les LDL, IDL, VLDL et leurs restes — qui portent chacune une molécule d'apolipoprotéine B à leur surface ; le nombre de particules (plutôt que la masse de cholestérol seule) est un facteur clé de l'athérosclérose car chaque particule peut être retenue dans la paroi artérielle. (triglyceride-rich remnants and Lp(a)) rather than to a non-ApoB mechanism of initiation [5], [40].

Clinical Phenotype	Expected Plaque Burden	Event Risk Probability
Ideal phenotype (lifelong LDL-C ~15 mg/dL)	Zero / undetectable	Effectively zero [15]
Healthy adult (lifelong LDL-C ~70 mg/dL)	Minimal / aging-related	Low (~5–10%) [14]
Western adult (lifelong LDL-C ~130 mg/dL)	Progressive / mature	High [2], [14]
Secondary prevention (achieved LDL-C ~15 mg/dL)	Stable / calcified	Significant residual [34]

Conclusion: Redefining the Threshold of Human Health

The evaluation of the zero-risk hypothesis supports the view that atherosclerosis is a substrate-dependent disease requiring a minimum lifelong cumulative exposure to ApoB-containing lipoproteins to initiate [2], [14]. The quantitative relationship between cumulative exposure and plaque formation implies that maintaining LDL-C in the 10–20 mg/dL range from birth delays disease initiation beyond the biological limits of human longevity [13], [15].

Genetic models (abetalipoproteinemia, homozygous FHBL, and healthy ultra-low phenotypes from PCSK9 and ANGPTL3 loss of function) demonstrate that such low levels are both safe and compatible with a marked reduction—and in some cases apparent absence—of atherosclerotic plaque, acknowledging that case numbers remain limited [19], [22], [24], [25]. While residual risks driven by Lp(a), remnants, and inflammation persist in patients with mature disease, these factors are insufficient to initiate atherogenesis in the near-total absence of ApoB particles [2], [40].

The implication for preventive cardiology is substantial [3]. Rather than managing risk as an inevitable consequence of aging, the proper objective is prévention primordialePrimordial prevention is a strategy aimed at stopping the development of cardiovascular risk factors in the first place—rather than treating risk factors or existing disease—by keeping atherogenic exposures near zero from birth or early life. It is distinguished from primary prevention, which targets people who already have risk factors but no clinical disease.: maintaining physiologic lipoprotein levels throughout the earliest stages of life to eliminate the substrate for atherogenesis [2], [15]. This paradigm suggests that heart disease—the leading cause of death worldwide—is biologically eradicable if ApoB particle retention is prevented throughout the human lifespan [2], [14].

Références

1. J. Borén, M. J. Chapman, R. M. Krauss, C. J. Packard, J. F. Bentzon, C. J. Binder, M. J. Daemen, L. L. Demer, R. A. Hegele, S. J. Nicholls, B. G. Nordestgaard, G. F. Watts, E. Bruckert, S. Fazio, B. A. Ference, I. Graham, J. D. Horton, U. Landmesser, U. Laufs, L. Masana, G. Pasterkamp, F. J. Raal, K. K. Ray, H. Schunkert, M.-R. Taskinen, B. van de Sluis, O. Wiklund, L. Tokgözoğlu, A. L. Catapano, and H. N. Ginsberg, “Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights—a consensus statement from the European Atherosclerosis Society Consensus Panel,” Eur. Heart J., vol. 41, no. 24, pp. 2313–2330, Jun. 2020, doi: 10.1093/eurheartj/ehz962.
2. B. A. Ference, H. N. Ginsberg, I. Graham, K. K. Ray, C. J. Packard, E. Bruckert, R. A. Hegele, R. M. Krauss, F. J. Raal, H. Schunkert, G. F. Watts, J. Borén, S. Fazio, J. D. Horton, L. Masana, S. J. Nicholls, B. G. Nordestgaard, B. van de Sluis, M.-R. Taskinen, L. Tokgözoğlu, U. Landmesser, U. Laufs, O. Wiklund, J. K. Stock, M. J. Chapman, and A. L. Catapano, “Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies,” Eur. Heart J., vol. 38, no. 32, pp. 2459–2472, Aug. 2017, doi: 10.1093/eurheartj/ehx144.
3. A. L. Catapano, I. Graham, G. De Backer, O. Wiklund, M. J. Chapman, H. Drexel, A. W. Hoes, C. S. Jennings, U. Landmesser, T. R. Pedersen, Ž. Reiner, G. Riccardi, M.-R. Taskinen, L. Tokgözoğlu, W. M. M. Verschuren, P. Vlachopoulos, D. A. Wood, and J. L. Zamorano, “2016 ESC/EAS guidelines for the management of dyslipidaemias,” Eur. Heart J., vol. 37, no. 39, pp. 2999–3058, Oct. 2016, doi: 10.1093/eurheartj/ehw272.
4. J. H. O’Keefe, L. Cordain, W. H. Harris, R. M. Moe, and R. Vogel, “Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal,” J. Am. Coll. Cardiol., vol. 43, no. 11, pp. 2142–2146, Jun. 2004, doi: 10.1016/j.jacc.2004.03.046.
5. B. G. Nordestgaard, M. J. Chapman, K. Ray, J. Borén, F. Andreotti, G. F. Watts, H. Ginsberg, P. Amarenco, A. Catapano, O. S. Descamps, E. Fisher, P. T. Kovanen, J. A. Kuivenhoven, P. Lesnik, L. Masana, Z. Reiner, M. R. Taskinen, L. Tokgözoğlu, and A. Tybjærg-Hansen, “Lipoprotein(a) as a cardiovascular risk factor: current status,” Eur. Heart J., vol. 31, no. 23, pp. 2844–2853, Dec. 2010, doi: 10.1093/eurheartj/ehq386.
6. B. G. Nordestgaard and A. Varbo, “Triglycerides and cardiovascular disease,” Lancet, vol. 384, no. 9943, pp. 626–635, Aug. 2014, doi: 10.1016/S0140-6736(14)61177-6.
7. I. Tabas, K. J. Williams, and J. Borén, “Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications,” Circulation, vol. 116, no. 16, pp. 1832–1844, Oct. 2007, doi: 10.1161/CIRCULATIONAHA.106.676890.
8. P. Libby, “The changing landscape of atherosclerosis,” Nature, vol. 592, no. 7855, pp. 524–533, Apr. 2021, doi: 10.1038/s41586-021-03392-8.
9. D. C. Schwenke and T. E. Carew, “Initiation of atherosclerotic lesions in cholesterol-fed rabbits. II. Selective retention of LDL vs. selective increases in LDL permeability in susceptible sites of arteries,” Arteriosclerosis, vol. 9, no. 6, pp. 908–918, Nov./Dec. 1989, doi: 10.1161/01.atv.9.6.908.
10. R. Ross, “Atherosclerosis—an inflammatory disease,” N. Engl. J. Med., vol. 340, no. 2, pp. 115–126, Jan. 1999, doi: 10.1056/NEJM199901143400207.
11. F. Mach, C. Baigent, A. L. Catapano, K. C. Koskinas, M. Casula, L. Badimon, M. J. Chapman, G. G. De Backer, V. Delgado, B. A. Ference, I. M. Graham, A. Halliday, U. Landmesser, B. Mihaylova, T. R. Pedersen, G. Riccardi, D. J. Richter, M. S. Sabatine, M.-R. Taskinen, L. Tokgözoğlu, and O. Wiklund, “2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk,” Eur. Heart J., vol. 41, no. 1, pp. 111–188, Jan. 2020, doi: 10.1093/eurheartj/ehz455.
12. A. R. Tall and L. Yvan-Charvet, “Cholesterol, inflammation and innate immunity,” Nat. Rev. Immunol., vol. 15, no. 2, pp. 104–116, Feb. 2015, doi: 10.1038/nri3793.
13. J. Brandts and K. K. Ray, “The LDL cumulative exposure hypothesis: evidence and practical applications,” Nat. Rev. Cardiol., vol. 21, no. 9, pp. 600–608, Sep. 2024, doi: 10.1038/s41569-024-01039-5.
14. M. J. Domanski, X. Tian, C. O. Wu, J. P. Reis, A. K. Dey, Y. Gu, L. Zhao, S. Bae, K. Liu, A. A. Hasan, D. Zimrin, M. R. Farkouh, A. R. Hong, D. M. Lloyd-Jones, and V. Fuster, “Time course of LDL cholesterol exposure and cardiovascular disease event risk,” J. Am. Coll. Cardiol., vol. 76, no. 13, pp. 1507–1516, Sep. 2020, doi: 10.1016/j.jacc.2020.07.059.
15. B. A. Ference, W. Yoo, I. Alesh, N. Mahajan, K. K. Mirowska, A. Mewada, J. Kahn, L. Afonso, K. A. Williams, and J. M. Flack, “Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis,” J. Am. Coll. Cardiol., vol. 60, no. 25, pp. 2631–2639, Dec. 2012, doi: 10.1016/j.jacc.2012.09.017.
16. R. Detrano, A. D. Guerci, J. J. Carr, D. E. Bild, G. Burke, A. R. Folsom, K. Liu, S. Shea, M. Szklo, D. A. Bluemke, D. H. O’Leary, R. Tracy, K. Watson, N. D. Wong, and R. A. Kronmal, “Coronary calcium as a predictor of coronary events in four racial or ethnic groups,” N. Engl. J. Med., vol. 358, no. 13, pp. 1336–1345, Mar. 2008, doi: 10.1056/NEJMoa072100.
17. S. Yusuf, S. Hawken, S. Ôunpuu, T. Dans, A. Avezum, F. Lanas, M. McQueen, A. Budaj, P. Pais, J. Varigos, and L. Lisheng, “Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study,” Lancet, vol. 364, no. 9438, pp. 937–952, Sep. 2004, doi: 10.1016/S0140-6736(04)17018-9.
18. A. L. Baggish, R. B. Weiner, G. Kanayama, J. I. Hudson, M. H. Picard, A. M. Hutter Jr., and H. G. Pope Jr., “Cardiovascular toxicity of illicit anabolic-androgenic steroid use,” Circulation, vol. 135, no. 21, pp. 1991–2002, May 2017, doi: 10.1161/CIRCULATIONAHA.116.026945.
19. A. J. Hooper, B. A. Burnett, and J. R. Burnett, “Abetalipoproteinemia,” GeneReviews® [Internet], Univ. of Washington, Seattle, updated Jul. 2023. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK532447/.
20. J. C. Cohen, E. Boerwinkle, T. H. Mosley Jr., and H. H. Hobbs, “Sequence variations in PCSK9, low LDL, and protection against coronary heart disease,” N. Engl. J. Med., vol. 354, no. 12, pp. 1264–1272, Mar. 2006, doi: 10.1056/NEJMoa054013.
21. M. M. Berriot-Varoqueaux, L. P. Aggerbeck, M. Samson-Bouma, and J. R. Wetterau, “The role of the microsomal triglyceride transfer protein in abetalipoproteinemia,” Annu. Rev. Nutr., vol. 20, pp. 663–697, 2000, doi: 10.1146/annurev.nutr.20.1.663.
22. S. G. Young and A. J. Hooper, “APOB-related familial hypobetalipoproteinemia,” GeneReviews® [Internet], Univ. of Washington, Seattle, updated Feb. 2021. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK570370/.
23. L. Tarugi, E. Averna, E. Di Leo, A. Cefalù, D. Noto, S. Magnolo, M. Cattin, S. Bertolini, and M. Calandra, “Molecular diagnosis of hypobetalipoproteinemia: an ENID review,” Atherosclerosis, vol. 195, no. 2, pp. e19–e27, Dec. 2007, doi: 10.1016/j.atherosclerosis.2007.05.003.
24. Z. Zhao, Y. Tuakli-Wosornu, T. A. Lagace, L. Kinch, N. V. Grishin, J. D. Horton, J. C. Cohen, and H. H. Hobbs, “Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote,” Am. J. Hum. Genet., vol. 79, no. 3, pp. 514–523, Sep. 2006, doi: 10.1086/507488.
25. N. O. Stitziel, A. V. Khera, X. Wang, A. J. Bierhals, A. C. Vourakis, A. E. Sperry, P. Natarajan, D. Klarin, C. A. Emdin, S. M. Zekavat, A. Nomura, J. Erdmann, H. Schunkert, N. J. Samani, W. E. Kraus, S. H. Shah, B. Yu, E. Boerwinkle, D. J. Rader, N. Gupta, P. M. Frossard, A. Rasheed, J. Danesh, E. S. Lander, S. Gabriel, D. Saleheen, K. Musunuru, and S. Kathiresan, “ANGPTL3 deficiency and protection against coronary artery disease,” J. Am. Coll. Cardiol., vol. 69, no. 16, pp. 2054–2063, Apr. 2017, doi: 10.1016/j.jacc.2017.02.030.
26. F. E. Dewey, V. Gusarova, R. L. Dunbar, C. O’Dushlaine, C. Schurmann, O. Gottesman, S. McCarthy, C. V. Van Hout, S. Bruse, H. M. Dansky, J. B. Leader, M. F. Murray, M. D. Ritchie, H. L. Kirchner, D. H. Ledbetter, J. Penn, A. Lopez, I. B. Borecki, J. D. Overton, J. G. Reid, D. J. Carey, A. J. Murphy, G. D. Yancopoulos, A. Baras, J. Gromada, and A. R. Shuldiner, “Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease,” N. Engl. J. Med., vol. 377, no. 3, pp. 211–221, Jul. 2017, doi: 10.1056/NEJMoa1612790.
27. K. Musunuru, J. P. Pirruccello, R. Do, G. M. Peloso, C. Guiducci, C. Sougnez, K. V. Garimella, S. Fisher, J. Abreu, A. J. Barry, T. Fennell, E. Banks, L. Ambrogio, K. Cibulskis, A. Kernytsky, E. Gonzalez, N. Rudzicz, J. C. Engert, M. A. DePristo, M. J. Daly, J. C. Cohen, H. H. Hobbs, D. Altshuler, G. Schonfeld, S. B. Gabriel, P. Yue, and S. Kathiresan, “Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia,” N. Engl. J. Med., vol. 363, no. 23, pp. 2220–2227, Dec. 2010, doi: 10.1056/NEJMoa1002926.
28. C. Baigent, L. Blackwell, J. Emberson, L. E. Holland, C. Reith, N. Bhala, R. Peto, E. H. Barnes, A. Keech, J. Simes, and R. Collins (Cholesterol Treatment Trialists’ Collaboration), “Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials,” Lancet, vol. 376, no. 9753, pp. 1670–1681, Nov. 2010, doi: 10.1016/S0140-6736(10)61350-5.
29. Cholesterol Treatment Trialists’ (CTT) Collaboration, “Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials,” Lancet, vol. 385, no. 9976, pp. 1397–1405, Apr. 2015, doi: 10.1016/S0140-6736(14)61368-4.
30. C. P. Cannon, M. A. Blazing, R. P. Giugliano, A. McCagg, J. A. White, P. Theroux, H. Darius, B. S. Lewis, T. O. Ophuis, J. W. Jukema, G. M. De Ferrari, W. Ruzyllo, P. De Lucca, K. Im, E. A. Bohula, C. Reist, S. D. Wiviott, A. M. Tershakovec, T. A. Musliner, E. Braunwald, and R. M. Califf, “Ezetimibe added to statin therapy after acute coronary syndromes,” N. Engl. J. Med., vol. 372, no. 25, pp. 2387–2397, Jun. 2015, doi: 10.1056/NEJMoa1410489.
31. J. Silverman, L. A. Ballantyne, D. A. Bhatt, S. D. Wiviott, M. S. Sabatine, and Cholesterol Treatment Trialists, “Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis,” JAMA, vol. 316, no. 12, pp. 1289–1297, Sep. 2016, doi: 10.1001/jama.2016.13985.
32. M. S. Sabatine, R. P. Giugliano, A. C. Keech, N. Honarpour, S. D. Wiviott, S. A. Murphy, J. F. Kuder, H. Wang, T. Liu, S. M. Wasserman, P. S. Sever, and T. R. Pedersen, “Evolocumab and clinical outcomes in patients with cardiovascular disease,” N. Engl. J. Med., vol. 376, no. 18, pp. 1713–1722, May 2017, doi: 10.1056/NEJMoa1615664.
33. R. P. Giugliano, T. R. Pedersen, A. C. Keech, A. Park, S. D. Wiviott, S. A. Murphy, J. F. Kuder, H. Wang, T. Liu, J. Lopez, and M. S. Sabatine, “Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial,” Lancet, vol. 390, no. 10106, pp. 1962–1971, Oct. 2017, doi: 10.1016/S0140-6736(17)32290-0.
34. G. G. Schwartz, P. G. Steg, M. Szarek, D. L. Bhatt, V. A. Bittner, R. Diaz, J. M. Edelberg, S. G. Goodman, C. Hanotin, R. A. Harrington, J. W. Jukema, G. Lecorps, K. W. Mahaffey, A. Moryusef, R. Pordy, K. Quintero, M. T. Roe, W. J. Sasiela, J.-F. Tamby, P. Tricoci, H. D. White, A. M. Zeiher, and ODYSSEY OUTCOMES Committees and Investigators, “Alirocumab and cardiovascular outcomes after acute coronary syndrome,” N. Engl. J. Med., vol. 379, no. 22, pp. 2097–2107, Nov. 2018, doi: 10.1056/NEJMoa1801174.
35. C. M. Ballantyne, J. P. Kastelein, L. A. Leiter, S. J. Nicholls, and colleagues, “Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial,” Lancet, 2025 (advance online publication).
36. S. J. Nicholls, C. M. Ballantyne, and colleagues (CORALreef Lipids Investigators), “Efficacy and safety of enlicitide, an oral PCSK9 inhibitor, in adults with hypercholesterolemia: the Phase 3 CORALreef Lipids trial,” N. Engl. J. Med., 2025 (publication pending).
37. M. Bhandari, S. M. Nissen, and colleagues, “How low can you go? New evidence supports no lower bound to low-density lipoprotein cholesterol level in secondary prevention,” Circulation, vol. 147, no. 19, pp. 1433–1435, May 2023, doi: 10.1161/CIRCULATIONAHA.123.064041.
38. P. M. Ridker, N. Mora, L. Rose, and JUPITER Trial Study Group, “Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents,” Eur. Heart J., vol. 37, no. 17, pp. 1373–1379, May 2016, doi: 10.1093/eurheartj/ehw046.
39. P. Libby, P. M. Ridker, and G. K. Hansson, “Progress and challenges in translating the biology of atherosclerosis,” Nature, vol. 473, no. 7347, pp. 317–325, May 2011, doi: 10.1038/nature10146.
40. S. Tsimikas, “A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies,” J. Am. Coll. Cardiol., vol. 69, no. 6, pp. 692–711, Feb. 2017, doi: 10.1016/j.jacc.2016.11.042.
41. S. Tsimikas, H.-K. Gordts, C. Nora, C. Yeang, and J. L. Witztum, “Statin therapy increases lipoprotein(a) levels,” Eur. Heart J., vol. 41, no. 24, pp. 2275–2284, Jun. 2020, doi: 10.1093/eurheartj/ehz310.
42. P. M. Ridker, B. M. Everett, T. Thuren, J. G. MacFadyen, W. H. Chang, C. Ballantyne, F. Fonseca, J. Nicolau, W. Koenig, S. D. Anker, J. J. P. Kastelein, J. H. Cornel, P. Pais, D. Pella, J. Genest, R. Cifkova, A. Lorenzatti, T. Forster, Z. Kobalava, L. Vida-Simiti, M. Flather, H. Shimokawa, H. Ogawa, M. Dellborg, P. R. F. Rossi, R. P. T. Troquay, P. Libby, R. J. Glynn, and CANTOS Trial Group, “Antiinflammatory therapy with canakinumab for atherosclerotic disease,” N. Engl. J. Med., vol. 377, no. 12, pp. 1119–1131, Sep. 2017, doi: 10.1056/NEJMoa1707914.
43. A. Daugherty, S. E. Tall, M. J. Daemen, E. Falk, E. M. Fisher, E. Garcia-Cardena, A. R. Lusis, A. P. Owens III, M. E. Rosenfeld, and I. Tabas, “Recommendation on design, execution, and reporting of animal atherosclerosis studies: a scientific statement from the American Heart Association,” Arterioscler. Thromb. Vasc. Biol., vol. 37, no. 9, pp. e131–e157, Sep. 2017, doi: 10.1161/ATV.0000000000000062.
44. M. J. Budoff, S. Achenbach, R. S. Blumenthal, J. J. Carr, J. G. Goldin, P. Greenland, A. D. Guerci, J. A. Lima, D. J. Rader, G. D. Rubin, L. J. Shaw, S. E. Wiegers, American Heart Association Committee on Cardiovascular Imaging and Intervention, American Heart Association Council on Cardiovascular Radiology and Intervention, American Heart Association Committee on Cardiac Imaging, “Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the AHA,” Circulation, vol. 114, no. 16, pp. 1761–1791, Oct. 2006, doi: 10.1161/CIRCULATIONAHA.106.178458.
45. H. S. Hecht, “Coronary artery calcium scanning: past, present, and future,” JACC Cardiovasc. Imaging, vol. 8, no. 5, pp. 579–596, May 2015, doi: 10.1016/j.jcmg.2015.02.006.
46. K. Nasir, M. B. Rivera, R. Blankstein, M. J. Blaha, A. D. Choi, R. S. Blumenthal, M. G. Silverman, A. Dardari, J. Berman, J. Yeboah, M. J. Budoff, J. J. Carr, and M. Cainzos-Achirica, “Implications of coronary artery calcium testing for primary prevention,” J. Am. Coll. Cardiol., vol. 66, no. 15, pp. 1657–1668, Oct. 2015, doi: 10.1016/j.jacc.2015.07.066.
47. S. E. Nissen, S. J. Nicholls, I. Sipahi, P. Libby, J. S. Raichlen, C. M. Ballantyne, J. Davignon, R. Erbel, J. C. Fruchart, J.-C. Tardif, P. Schoenhagen, T. Crowe, V. Cain, K. Wolski, M. Goormastic, and E. M. Tuzcu, “Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial,” JAMA, vol. 295, no. 13, pp. 1556–1565, Apr. 2006, doi: 10.1001/jama.295.13.jpc60002.
48. S. E. Nissen, S. J. Nicholls, K. Wolski, R. Nesto, S. Kupfer, A. Perez, H. Jure, R. De Larochellière, C. S. Staniloae, K. Mavromatis, J. Saw, B. Hu, A. M. Lincoff, E. M. Tuzcu, and PERISCOPE Investigators, “Effect of rosuvastatin versus atorvastatin on progression of coronary atherosclerosis in patients with coronary artery disease (SATURN),” N. Engl. J. Med., vol. 365, no. 22, pp. 2078–2087, Dec. 2011, doi: 10.1056/NEJMoa1110874.
49. S. J. Nicholls, R. Puri, T. Anderson, C. M. Ballantyne, L. Cho, J. J. P. Kastelein, W. Koenig, R. Somaratne, H. Kassahun, J. Yang, S. M. Wasserman, R. Scott, I. Ungi, J. Podolec, A. O. Ophuis, J. H. Cornel, M. Borgman, D. M. Brennan, and S. E. Nissen, “Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial,” JAMA, vol. 316, no. 22, pp. 2373–2384, Dec. 2016, doi: 10.1001/jama.2016.16951.
50. A. V. Khera, E. S. Everett, M. G. Caulfield, F. E. Hantgan, J. Deasy, R. K. Scott, P. S. Sever, J. Barton, L. Heller, A. Nambi, and M. S. Sabatine, “Evolocumab, plaque regression, and clinical outcomes,” J. Am. Coll. Cardiol., vol. 75, no. 9, pp. 1037–1050, Mar. 2020, doi: 10.1016/j.jacc.2019.12.052.
51. D. J. Rader and G. K. Hovingh, “HDL and cardiovascular disease,” Lancet, vol. 384, no. 9943, pp. 618–625, Aug. 2014, doi: 10.1016/S0140-6736(14)61217-4.
52. R. C. Thompson, A. H. Allam, G. P. Lombardi, L. S. Wann, M. L. Sutherland, J. D. Sutherland, M. A. Soliman, B. Frohlich, D. T. Mininberg, J. M. Monge, C. M. Vallodolid, S. L. Cox, G. A. El-Maksoud, I. Badr, M. I. Miyamoto, A. el-Halim Nur el-Din, J. Narula, C. E. Finch, and G. S. Thomas, “Atherosclerosis across 4000 years of human history: the Horus study of four ancient populations,” Lancet, vol. 381, no. 9873, pp. 1211–1222, Apr. 2013, doi: 10.1016/S0140-6736(13)60598-X.
53. H. Kaplan, R. C. Thompson, B. C. Trumble, L. S. Wann, A. H. Allam, B. Beheim, B. Frohlich, M. L. Sutherland, J. D. Sutherland, J. Stieglitz, D. E. Rodriguez, D. E. Michalik, C. J. Rowan, G. P. Lombardi, R. Bedi, C. E. Garcia, J. K. Min, J. Narula, C. E. Finch, M. Gurven, and G. S. Thomas, “Coronary atherosclerosis in indigenous South American Tsimane: a cross-sectional cohort study,” Lancet, vol. 389, no. 10080, pp. 1730–1739, Apr. 2017, doi: 10.1016/S0140-6736(17)30752-3.